Pharmaceuticals

ALTAMIRA THERAPEUTICS LTD

Altamira Medica Obtains EU MDR Certification for Bentrio Nasal Spray

Altamira Therapeutics Ltd released FY2025 Q1 earnings on August 29 (EST), actual revenue USD 0, actual EPS USD -0.1529

Altamira Therapeutics Ltd released FY2025 Semi-Annual Earnings on August 29 Pre-Market (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -0.3059 (Forecast: USD --)

Altamira Therapeutics Ltd released FY2025 Q2 earnings on August 29 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.1529

Altamira Therapeutics Ltd. plans to reduce operating expenses by partially divesting its ATAG subsidiary

Altamira Therapeutics Reports 2025 First Half Year Financials and Advances RNA Delivery Technology

ALTAMIRA THERAPEUTICS LTD to Release FY2025 Semi-Annual Earnings on August 29, 2025 (EST), Forecast Revenue USD 0, EPS --

Altamira Therapeutics Ltd released FY2024 9 Months Earnings on April 30 (EST), Actual Revenue: USD 0, Actual EPS: USD -2.6773

Altamira Therapeutics Ltd released FY2024 Q3 earnings on April 30, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5713

Altamira Therapeutics Ltd released FY2024 Q4 earnings on April 30 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.5713

Altamira Therapeutics Ltd released FY2024 earnings on April 30 Pre-Market EST, actual revenue USD 0, actual EPS USD -2.9861

Altamira Therapeutics Ltd to Release FY2024 Earnings Report on April 30, 2025 Pre-Market EST

Altamira Therapeutics Ltd released FY2023 Q1 earnings on September 24, 2024 (EST) with actual revenue of 0 USD and EPS of -14.1571 USD

Altamira Therapeutics Ltd released FY2024 Q1 earnings on September 24, 2024 (EST) with actual revenue of 0 USD and EPS of -1.0529 USD

Altamira Therapeutics Ltd released FY2024 Q2 earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -1.0529 USD

Altamira Therapeutics Ltd released FY2023 Q2 earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -14.1571 USD

Altamira Therapeutics Ltd released FY2023 Semi-Annual Earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -28.3142 USD

Altamira Therapeutics Ltd released FY2024 Semi-Annual Earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -2.1059 USD

Altamira Therapeutics Ltd released FY2021 Q3 earnings on April 10, 2024 (EST) with actual revenue of 0 USD and EPS of 0 USD

Altamira Therapeutics Ltd released FY2022 Q3 earnings on April 10, 2024 (EST) with actual revenue of 0 USD and EPS of 0 USD

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

DigitalBridge

Irobot

Toro

Praxis Precision Medicines

Alumis

Dreamland

High Roller Tech

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap